Epizyme Struts Back To Wall Street, Plans $140 Million Raise

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Epizyme saw its stock jump up a few weeks ago after hitting a milestone in its big partnership with Celgene. Now it plans to use some of that momentum to raise some more cash from public investors. On Monday morning, Cambridge, MA-based Epizyme (NASDAQ: EPZM) filed papers with the Securities and Exchange Commission showing it plans to raise as much as $140 million in cash through a public offering of stock.

Help employers find you! Check out all the jobs and post your resume.

Back to news